Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Piedmont Realty Trust prices USD 200 million exchangeable senior notes offering due 2031

Piedmont Realty Trust prices USD 200 million exchangeable senior notes offering due 2031

ReutersReuters2026/09/15 02:52
  • Piedmont Realty Trust priced a private offering of USD 200 million 2.875% exchangeable senior notes due 2031, with a USD 30 million upsize option.
  • Net proceeds estimated at about USD 194.3 million, rising to about USD 223.5 million if the upsize option is fully exercised.
  • Proceeds earmarked to redeem outstanding 9.250% senior notes due 2028, using additional funding sources including ATM forwards, cash, revolver borrowings.
  • About USD 50 million allocated to repurchase 5,434,782 common shares at USD 9.2 in a concurrent privately negotiated transaction.
  • Notes settle Sept. 17; initial exchange price set at USD 12.65 a share, a 37.5% premium to the Sept. 14 close.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Piedmont Realty Trust Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609142251PRIMZONEFULLFEED9826865) on September 15, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage